Detalhe da pesquisa
1.
Long-term evaluation of the safety and efficacy of recombinant human pentraxin-2 (rhPTX-2) in patients with idiopathic pulmonary fibrosis (IPF): an open-label extension study.
Respir Res
; 23(1): 129, 2022 May 21.
Artigo
Inglês
| MEDLINE | ID: mdl-35597980
2.
Extracellular Mitochondrial DNA Is Generated by Fibroblasts and Predicts Death in Idiopathic Pulmonary Fibrosis.
Am J Respir Crit Care Med
; 196(12): 1571-1581, 2017 12 15.
Artigo
Inglês
| MEDLINE | ID: mdl-28783377
3.
Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial.
JAMA
; 319(22): 2299-2307, 2018 06 12.
Artigo
Inglês
| MEDLINE | ID: mdl-29800034
4.
A Clinic Blueprint for Post-Coronavirus Disease 2019 RECOVERY: Learning From the Past, Looking to the Future.
Chest
; 159(3): 949-958, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33159907
5.
Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
Lab Invest
; 90(6): 812-23, 2010 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-20404807
6.
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
Lancet Respir Med
; 7(8): 657-664, 2019 08.
Artigo
Inglês
| MEDLINE | ID: mdl-31122893